-
Mashup Score: 0Benefits of post CAR-T alloHSCT consolidation therapy in B-ALL - 4 year(s) ago
While patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with chimeric antigen receptor (CAR) T-cell therapy usually experience high initial…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The microbiota as a biomarker for GvHD - 4 year(s) ago
Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, gives an overview of recent research into biomarkers and prognostication for graft-versus-host…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ernst Holler of @uni_regensburg summarizes recent research on biomarkers and prognostication for #GvHD. 👉Watch here: https://t.co/YXFygOGmpQ👈 @COSTEMCongress #COSTEM21 #GvHD #HemOnc
-
-
Mashup Score: 2The role of upfront double auto-SCT in high-risk myeloma - 4 year(s) ago
Sergio Giralt, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the role of double autologous stem…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sergio Giralt (@sgiraltbmtdoc) of @sloan_kettering discusses the role of double auto-SCT in the treatment of high-risk #MultipleMyeloma. 👉Watch here: https://t.co/EEXyt5Oghy👈 @COSTEMCongress #COSTEM21 #Myeloma #MMSM #BMTsm #ImmunoOnc #HemOnc
-
-
Mashup Score: 4Recent advances in the management of cGvHD - 4 year(s) ago
Hildegard Greinix, MD, Medical University of Graz, Graz, Austria, gives an overview of her presentation on recent advances in the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 Hildegard Greinix of @MedUni_Wien comments on recent advances in the management of cGvHD, focusing on the use of ruxolitinib as a second-line treatment for cGvHD 🩸💊 Watch now🎥: https://t.co/wvlDdjIMGG @COSTEMCongress #COSTEM21 #GvHD #HemOnc #BMTsm #TrialUpdate #CTSM
-
-
Mashup Score: 3Management of patients with relapsed Hodgkin lymphoma - 4 year(s) ago
Michael Bishop, MD, University of Chicago, Chicago, IL, explains the different strategies used to treat patients with Hodgkin lymphoma who…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Michael Bishop (@mrbishop_UC_BMT), of @UChicago talks on the management of patients with relapsed #HodgkinLymphoma🩸💊 👉https://t.co/IGCJlG67Jf @COSTEMCongress #COSTEM21 #Lymphoma #HemOnc #BMTsm
-
-
Mashup Score: 1
Gösta Gahrton, MD, Karolinska University Hospital, Stockholm, Sweden, discusses the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as salvage…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gösta Garthon of @karolinskainst discusses allo-HSCT as salvage therapy in #MultipleMyeloma with auto-HSCT or to consolidate CAR-T therapy. ➡️Watch here: https://t.co/WYdom0W8fA⬅️ @COSTEMCongress #COSTEM21 #Myeloma #MMSM #BMTsm #CART #ImmunoOnc #HemOnc
-
-
Mashup Score: 0
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses whether the graft-versus-leukemia (GvL) effect is stronger when using a…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Arnon Nagler (@nagler_EBMT) of @SHEBA_ discusses graft-versus-#Leukemia in haploidentical and unrelated donors for AML patients. 👉Watch here: https://t.co/flYx5HqZPK👈 @COSTEMCongress #COSTEM21 #GvHD #Leusm #AMLsm #BMTsm #HemOnc
-
-
Mashup Score: 1Next steps for improving dual CARs - 4 year(s) ago
Nirali Shah, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD, comments on the efficacy of dual chimeric antigen…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nirali Shah (@NiraliShahMD) of @theNCI comments on the high potential of dual CARs and the research needed to improve efficacy. ➡️Watch here: https://t.co/FCcM09LDuW @COSTEMCongress #COSTEM21 #ImmunoOnc #CART #HemOnc #tcellrx
-
-
Mashup Score: 0Early allogeneic transplantation for myelofibrosis patients responding to ruxolitinib - 4 year(s) ago
Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clínico Universitario Valencia, Valencia, Spain, discusses the role of early allogeneic transplantation for patients…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Juan Carlos Hernández-Boluda of @GVAclinic discusses early allo-STC in JAK2 inhibition responders in primary #Myelofibrosis. Watch here: https://t.co/YY27L3T6Og @COSTEMCongress #COSTEM21 #MPNsm #BMTsm #HemOnc
-
-
Mashup Score: 3The microbiota as a biomarker for GvHD - 4 year(s) ago
Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, gives an overview of recent research into biomarkers and prognostication for graft-versus-host…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Should gut decontamination be performed pre-transplant for #HemOnc patients? Ernst Holler discusses the pros & cons of gut decontamination pre-transplant 💭 Click to watch 👉https://t.co/XkPxOJjspM👈 @COSTEMCongress #COSTEM21 #MMsm #LEUsm #LYMsm #BMTsm
-
Peihua Lu of Lu Daopei Hospital discusses the benefit of consolidation therapy with allo-SCT after CAR-T therapy in B-cell acute lymphoblastic #Leukemia. ▶️Watch here: https://t.co/W63TsuvY4q @COSTEMCongress #COSTEM21 #ALLsm #Leusm #BMTsm #CART #ImmunoOnc #HemOnc